会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明授权
    • Methods of preparing novel dipeptide compounds or pharmaceutically acceptable salts thereof
    • 制备新型二肽化合物或其药学上可接受的盐的方法
    • US06222043B1
    • 2001-04-24
    • US09228009
    • 1999-01-08
    • Ryohei KatoTsutomu MimotoTominaga FukazawaNaoko MorohashiYoshiaki Kiso
    • Ryohei KatoTsutomu MimotoTominaga FukazawaNaoko MorohashiYoshiaki Kiso
    • C07D27706
    • C07D263/06C07D207/16C07D277/06
    • The present invention provides synthetic methodology to produce novel dipeptide compounds and pharmaceutically acceptable salts thereof which exhibit excellent HIV protease inhibitory activity and excellent bioavailability from digestive tracts. Methods of using the dipeptide compounds and pharmaceutically acceptable salts thereof also are provided. A non-limiting example of a dipeptide compound of the invention has the general formula (IA): where R1 represents a 5-membered or 6-membered monocyclic hydrocarbon group or heterocyclic group wherein 3 or fewer substituents other than hydrogen are present on the cyclic group; R21 and R22 each represents a hydrogen atom or a linear or branched aliphatic hydrocarbon group having 1-6 carbon atoms; and R3 represents a linear or branched aliphatic hydrocarbon group having 1-6 carbon atoms or a monovalent group comprising an aromatic monocyclic hydrocarbon group having 12 or fewer carbon atoms in total, wherein a halogen atom can be substituted on the aromatic ring of the aromatic monocyclic hydrocarbon group.
    • 本发明提供合成方法以产生新的二肽化合物及其药学上可接受的盐,其表现出优异的HIV蛋白酶抑制活性和从消化道获得优异的生物利用度。 还提供了使用二肽化合物及其药学上可接受的盐的方法。 本发明的二肽化合物的非限制性实例具有通式(IA):其中R 1表示5元或6元单环烃基或杂环基,其中3个或更少个除氢以外的取代基存在于环状 组; R 21和R 22各自表示氢原子或具有1-6个碳原子的直链或支链脂族烃基; R3表示具有1-6个碳原子的直链或支链脂族烃基或包含总共具有12个或更少碳原子的芳族单环烃基的一价基团,其中卤素原子可以在芳族单环的芳环上被取代 烃基。
    • 4. 发明授权
    • Cyclic tetrapeptide derivatives and medicinal use thereof
    • 环状四肽衍生物及其医药用途
    • US06399568B1
    • 2002-06-04
    • US09486783
    • 2000-03-01
    • Norikazu NishinoMinoru YoshidaSueharu HorinouchiYasuhiko KomatsuTsutomu Mimoto
    • Norikazu NishinoMinoru YoshidaSueharu HorinouchiYasuhiko KomatsuTsutomu Mimoto
    • A61K3812
    • C07K5/126A61K38/00
    • A cyclic tetrapeptide derivative represented by the general formula (I): wherein: R11, R12, R21 and R22 independently denote a monovalent group selected from hydrogen, a linear or branched alkyl group with 6 or less carbon atoms, benzyl group, 4-methoxybenzyl group, 3-indolylmethyl group, (N-methoxy-3-indolyl) methyl group, (N-formyl-3-indolyl)methyl group, etc.; R3 denotes a divalent group selected from a linear chained hydrocarbon group with 3 or 4 carbon atoms, or the linear branched hydrocarbon group having a branched chain added to the chain, or a divalent group substituted with a heteroatom; R4 denotes a divalent chained hydrocarbon group with 4 to 6 carbon atoms, or a divalent group derived from said hydrocarbon group by addition etc. of a branched chain on said chain; and a pharmaceutically acceptable salt thereof, or an analogous cyclic tetrapeptide derivative compound; as well as a histone deacetylase enzyme inhibitor, an MHC class-I molecule expression promoting agent and a pharmaceutical composition that comprise said cyclic tetrapeptide derivative as an effective ingredient.
    • 由通式(I)表示的环状四肽衍生物:其中:R11,R12,R21和R22独立地表示选自氢,碳原子数6以下的直链或支链烷基,苄基,4-甲氧基苄基 (3-甲氧基-3-吲哚基)甲基,(N-甲酰基-3-吲哚基)甲基等。 R3表示选自具有3或4个碳原子的直链状烃基或者在该链上添加有支链的直链支链烃基或被杂原子取代的二价基团的二价基团; R4表示二价链状烃基 或含有4〜6个碳原子的二价基团,或通过所述链上的支链的加成等衍生自所述烃基的二价基团; 和其药学上可接受的盐,或类似的环状四肽衍生物化合物; 以及组蛋白脱乙酰酶酶抑制剂,MHC class I分子表达促进剂和包含所述环状四肽衍生物作为有效成分的药物组合物。